From Zero to $1B

Akili

featured case study

An FDA Approved Digital Therapeutic: From Ground-Zero to IPO

Bringing an entirely new modality of medicine to market requires more than vision—it demands speed, strategic precision, and the ability to build trust in uncharted territory. At Akili, Meghan and her team led that charge.

Tasked with commercializing the first-ever FDA-cleared video game treatment for cognitive impairment, Meghan assembled and led a cross-functional team that built the full commercial infrastructure from the ground up in under six months—laying the operational and organizational foundation for a category-defining product launch.

Under her direction, the team crafted and executed a go-to-market strategy that touched every facet of the commercial journey: from customer engagement and market access to pricing and distribution. 

With no existing playbook for digital therapeutics at this scale, the team’s work under Meghan’s leadership helped establish a repeatable model for how digital medicine could reach patients—and get paid for.

The result? A record-setting Series D raise of $160 million to support launch and scale, followed by a $1B SPAC deal that took the company public. Akili didn’t just go to market—it became the market.

This case study reflects Meghan’s ability to mobilize high-performing teams, shape bold strategy, and deliver measurable impact—even in the most innovative and evolving spaces.